Project background & objectives

Lung cancer is the 2nd most common cancer in the world (3rd in France), with more than 2.2 million new cases diagnosed in 2020. The aim of this observational study is to set up a multicenter cohort providing a complete characterization of lung cancer patients.

This cohort is based on a standardized data model applicable to all types of cancer or oncology specialties (surgery, medical oncology, radiation oncology, pathology, radiology, etc.) to facilitate the exploitation of these data for clinical and research purposes. The cohort should provide a better understanding of disease progression and accelerate therapeutic innovation for lung cancer patients.

+5000

Patients included

+21

Participating centers

+80

Variables

The patient's voice

The Patients en Réseau association brings together patients and relatives affected by cancer, and was created on the basis of their experiences. Meet the Patients en Réseau association

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Participating centers

Inclusion criteria & study variables

The LUCC Lung Cancer cohort is open to all types of institutions and includes patients at all stages of the disease (metastatic and non-metastatic).

To be eligible for inclusion in the study, patients must meet the following criteria:

Histologically proven cancerous lung lesions;
Have received medical, surgical or other treatment for lung cancer at one of the study sites;
Have not objected to the collection, storage and processing of their personal health data.

‍

In order to provide the most exhaustive view possible of lung cancer patients, the cohort is made up of numerous variables covering the following areas:

Genre,
Date of birth,
vital status,

FAMILY NUMBER,
puberty etc...

FAMILY HISTORY OF AOH,
comorbidities,
AFFECTED FAMILY MEMBER(S) ETC...

DIAGNOSIS DATE,
DATE OF 1ST EXPERIMENT,
type of hereditary angioedema,

NATURE OF DEFICIT C1NH,
BIOLOGICAL CHECK-UP, ETC.

TREATMENT NAME,
DOSE,
FREQUENCY OF ADMINISTRATION,

SIDE EFFECT(S) ETC...

LOCATION OF THE CRISIS,
TRIGGERING FACTOR,
DURATION OF THE CRISIS,

TYPE OF TREATMENT,
treatment efficacy etc...

TYPE OF INTERCURRENT EVENT,
SHORT-TERM PROPHYLACTIC TREATMENT,
INTERCURRENT EVENT FOLLOWED BY A CRISIS ETC...

Genre,
Date of birth,
vital status,

DATE OF DEATH,
Cause of death etc...

SMOKING STATUS,
cannabis consumption,
vital status

DIAGNOSIS DATE,
METASTATIC AT DIAGNOSIS,
TNM STATUS AT DIAGNOSIS,

HISTOLOGICAL SUBTYPE,
metastatic sites,
MUTATIONS etc...

TYPE OF TREATMENT,
drugs used,
BETTER RESPONSE TO TREATMENT,

PROGRESSION ETC...

AGE,
SIZE,
WEIGHT,

SMOKING (PACKAGE/YEAR),
Allergies etc...

Patient with ENT symptoms,
cardiovascular disease,
nasosinus polyposis, etc...

Bronchodilator treatment(s),
NAME of bronchodilator,
dose of bronchodilator,

bronchodilator frequency etc...

Assessment of the number of exacerbations,
number of exacerbations,
reason for hospitalization etc...

GENRE,
DATE OF BIRTH,
vital status,

SMOKING (PACKAGE/YEAR),
Allergies etc...

SMOKING STATUS
ONCOLOGICAL HISTORY ETC...

Evaluation of eva,
Evaluation of das-28,
Anti-ccp ac results (u/ml),

Biopsy results etc...

symptomatic treatments
fund processing
biotherapies

stopping treatment etc...

Scientific Committee

Prof. Benhamin Besse

Medical oncologist specializing in the treatment of thoracic cancers and Director of Clinical Research at Gustave Roussy

Franck Le Ouay

Co-founder of Lifen

Laure Guéroult Accolas

Founder of the Patients en réseau association

Dr Sophie Cousin

Medical oncologist in the Early Stage Clinical Trials Unit and Sarcoma Unit at Institut Bergonié

Dr Renaud Descourt

Respiratory specialist at Brest University Hospital

Dr Judith Raimbourg

Medical oncologist at the Institut de cancérologie de l'ouest

Dr Carole Helissey

Medical oncologist at Hôpital d'Instruction des Armées Begin

Dr Nicolas Rezvoy

Radiation oncologist at La Louvière and Villeneuve d'Ascq private hospitals

Dr Sophie Schneider

Respirologist at the Centre hospitalier de la Cote Basque

Prof. Olaf Mercier

Thoracic surgeon, cardiopulmonary transplant and Professor at Paris-Saclay University

Prof. Virginie Westeel

Pneumology, thoracic oncology and respiratory allergology at Besançon University Hospital

Prof. Benhamin Besse

Medical oncologist specializing in the treatment of thoracic cancers and Director of Clinical Research at Gustave Roussy

Franck Le Ouay

Co-founder of Lifen

Laure Guéroult Accolas

Founder of the Patients en réseau association

Key dates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Posters & Publications

An AI-derived Tool to Pre-screen Lung Cancer Candidates for Clinical Trials

September 16, 2024

Using AI to automatically process data from unstructured health records of patients with lung cancer

April 9, 2024

Utilizing AI for Automated Data Entry and Analysis to Pre screen Lung Cancer Clinical Trial Candidates

September 9, 2024

An AI-derived Tool to Pre-screen Lung Cancer Candidates for Clinical Trials

September 16, 2024

Using AI to automatically process data from unstructured health records of patients with lung cancer

April 9, 2024

Utilizing AI for Automated Data Entry and Analysis to Pre screen Lung Cancer Clinical Trial Candidates

September 9, 2024

Research projects

Here you will find all the study projects using the cohort. These projects comply with the regulatory framework and have been approved in advance by the cohort's scientific committee:

Monarch project: Description of care pathways for patients with advanced or metastatic non-small-cell lung cancer with EGFR mutation

Patients

Why take part in the project?

Some of your medical and administrative data is collected when you are treated in a healthcare facility. This data is useful for the advancement of research.

This research, conducted in the public interest, aims to develop knowledge in order to develop new treatments or improve the overall management of patients suffering from the same disease as you. If you agree to your data being used for this study, you will not have to make any additional visits or undergo any additional examinations.

Only information already in your medical file will be collected. No directly identifying data (surname, first name or contact details) will be included in the cohorts.